Abstract | BACKGROUND & AIMS: MATERIALS AND METHODS: NASH-cirrhotic rats received 2-week brivanib, sorafenib or vehicle (NASH-cirrhotic+briv, NASH-cirrhotic+soraf and NASH-cirrhotic rats) were included for various measurements. RESULTS: In comparison with NASH-cirrhotic rats, significant decreased plasma VEGF, fibroblast growth factor, platelet-derived growth factor, hepatic tumour necrosis factor (TNFα), IL-1β, IL-6, IL-17 were accompanied by decreased leucocyte mass/activity ((99 m) Tc- phytate and (18) F-FDG SPECT/PET/CT scans), hepatic leucocytes recruitment/microvascular density (fluorescence-enhanced intravital microscopy) and hydroxyproline content, and increased hepatic blood flow in NASH-cirrhotic+briv and NASH-cirrhotic+soraf rats. In addition, increased hepatic microvasculatures compliance-related improved buffering effect of portal vein to acute mannitol infusion was associated with decreased circulating nitric oxide and aldosterone, plasma volume expansion ( dye dilution method), splanchnic blood pooling ((99 m) Tc-RBC SPECT/PET/CT scans), peripheral hypotension, portal hypertension and ascites in brivanib and sorafenib-treated NASH-cirrhotic rats. CONCLUSION: Besides antifibrotic, antiangiogenic and portal hypertensive effects, chronic antagonism of anti-VEGFR with brivanib and sorafenib improves hepatic blood flow, hepatic venous dysregulation, inhibits leucocytes recruitment/activation, splanchnic blood pooling and ascites formation in NASH-cirrhotic rats. Thus, brivanib and sorafenib might be ideal therapeutic agents in cirrhotic patients suffering from severe haemodynamic disarrangement and ascites.
|
Authors | Ying-Ying Yang, Ren-Shyan Liu, Pei-Chang Lee, Yi-Chen Yeh, Yi-Tsau Huang, Wei-Ping Lee, Kuei-Chuan Lee, Yun-Cheng Hsieh, Fa-Yauh Lee, Tat-Wei Tan, Han-Chieh Lin |
Journal | Liver international : official journal of the International Association for the Study of the Liver
(Liver Int)
Vol. 34
Issue 4
Pg. 521-34
(Apr 2014)
ISSN: 1478-3231 [Electronic] United States |
PMID | 23998651
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |
Chemical References |
- Cytokines
- DNA Primers
- Phenylurea Compounds
- Platelet-Derived Growth Factor
- Triazines
- Vascular Endothelial Growth Factor A
- Niacinamide
- Fibroblast Growth Factors
- Sorafenib
- brivanib
- Receptors, Vascular Endothelial Growth Factor
- Alanine
|
Topics |
- Alanine
(analogs & derivatives, pharmacology)
- Animals
- Ascites
(drug therapy)
- Cytokines
(metabolism)
- DNA Primers
(genetics)
- Fatty Liver
(drug therapy, pathology)
- Fibroblast Growth Factors
(blood)
- Microcirculation
(drug effects, physiology)
- Niacinamide
(analogs & derivatives, pharmacology)
- Non-alcoholic Fatty Liver Disease
- Phenylurea Compounds
(pharmacology)
- Platelet-Derived Growth Factor
(metabolism)
- Positron-Emission Tomography
- Rats
- Receptors, Vascular Endothelial Growth Factor
(antagonists & inhibitors)
- Reverse Transcriptase Polymerase Chain Reaction
- Sorafenib
- Splanchnic Circulation
(drug effects)
- Triazines
(pharmacology)
- Vascular Endothelial Growth Factor A
(blood)
|